Amgen to buy biotech startup TeneoBio
Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →
Read More →Takeda expansion is latest coup for Conejo Valley pharma industry
Takeda Pharmaceuticals, a Japanese company with major operations in the Conejo Valley, will expand its facility in Thousand Oaks, investing $126 million to build out the manufacturing operations to support new product lines. The Takeda team, alongside the mayor of Thousand Oaks, Claudia Bill-de la Peña, is scheduled to hold a groundbreaking ceremony for the Read More →
Read More →FDA accuses Amgen of misleading advertising
The U.S. Food and Drug Administration tagged Amgen with a letter July 7 that says the Thousand Oaks biotech firm made “misleading claims” in advertisements for its drug Neulasta, by suggesting it is more effective than biosimilar competitors. Neulasta is a prescription medication used to reduce infection risk from febrile neutropenia (a low level of Read More →
Read More →FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
Read More →Arcutis ends phase 2 trials on potential skin treatment
Shares of Westlake Village-based Arcutis Biotherapeutics dropped by as much as 5% during the trading day July 1, after the biotech company terminated phase 2 trials for a potential treatment. Arcutis, a biotech company focused on creating dermatology treatments, has announced July that it had terminated phase 2a and 2b trials for evaluating ARQ-252, a Read More →
Read More →
Biotech’s movers and shakers gather for BioMedley
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen’s new drug could be a blockbuster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
